Strata Critical Medical (SRTA) Gross Profit (2021 - 2026)

Strata Critical Medical (SRTA) has reported Gross Profit for 6 consecutive years, with $14.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gross Profit rose 100.16% year-over-year to $14.1 million; the TTM figure through Mar 2026 stood at $55.1 million (up 53.46% YoY), while the FY2025 annual figure was $41.1 million, up 38.99% from the prior year.
• Gross Profit advanced to $14.1 million in Q1 2026 per SRTA's latest filing, from $11.7 million in the prior quarter.
• Across five years, Gross Profit topped out at $17.7 million in Q2 2025 and bottomed at $2.9 million in Q1 2022.
• Historically, Gross Profit has averaged $10.3 million across 5 years, with a median of $10.1 million in 2024.
• Annual changes were most pronounced in 2022 — Gross Profit plunged 60.29% — and 2023, when it soared 145.09%.
• Strata Critical Medical's Gross Profit stood at $8.0 million in 2022, then rose by 12.15% to $9.0 million in 2023, then slumped by 44.35% to $5.0 million in 2024, then jumped by 132.75% to $11.7 million in 2025, then advanced by 20.97% to $14.1 million in 2026.
• Business Quant data shows SRTA's Gross Profit at $14.1 million in Q1 2026, $11.7 million in Q4 2025, and $11.6 million in Q3 2025.